海思科(002653.SZ)：获得创新药HSK47977片的药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for its self-developed oral BCL6 PROTAC small molecule drug, HSK47977, aimed at treating non-Hodgkin lymphoma [1] Group 1: Drug Development - HSK47977 targets and degrades the BCL6 protein, inhibiting the occurrence and development of tumor cells [1] - The drug is classified as a Class 1 chemical drug according to the regulations set forth in the announcement on chemical drug registration classification [1] - Preclinical studies have shown that HSK47977 exhibits strong anti-tumor activity, high target selectivity, and an ideal safety window [1] Group 2: Combination Therapy - HSK47977 can achieve a synergistic anti-cancer effect when used in combination with BCL2 inhibitors, indicating its significant development potential [1]